× We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click our cookies policy for information on how to change your cookie settings.


meta|Evidence - COVID-19

Live meta-analysis and evidence synthesis of therapies for COVID19

tutorial video
En     Fr

Our approach


adjuvant therapies

anticoagulant 2

Bivalirudin

colchicine 3

face mask

febuxostat

hydrogen-oxygen nebulizer

hyperbaric oxygen

nintedanib

pulmonary rehabilitation

thalidomide

vitamin C

anti-inflammatoty and immuno-therapy

acalabrutinib 2

anti-inflammatory therapies 1

IFX-1

naproxen, ibuprofen

non-steroidal anti-inflammatory drugs 3

Celecoxib 1

Ibuprofen 2

sodium aescinate

Apilimod

corticosteroids 8

ciclesonide

dexamethasone 2

Hydrocortisone 2

inhaled steroids

low-dose corticosteroids

methylprednisolone 2

imatinib

Immunostimulants drugs

anti-PD-1 antibody

CD24Fc

convalescent plasma treatment 12

immunoglobulin therapy

emapalumab

inactivated mycobacterium vaccine

interferon 4

interferon / TFF2 1

SNG001 inhaled interferon beta 1

Interleukin-2

neutralizing antibody

bamlanivimab (LY-CoV555)

rhG-CSF

Vitamin D 5

Immunosuppressants drugs

anakinra 2

anti-interleukin-6

clazakizumab

sarilumab 3

sarilumab azithromycin hydroxychloroquine

sarilumab high dose (400mg) 1

sarilumab low dose (200mg) 1

siltuximab

tocilizumab 17

baricitinib

eculizumab

jakotinib

lenzilumab

ruxolitinib

tacrolimus

tetrandrine

leflunomide

pirfenidone

Polyinosinic-Polycytidylic Acid

sargramostim

thymosin

antiviral and associated therapy

ASC09/ritonavir

azithromycin 2

azvudine

baloxavir marboxil

bromhexine

carrimycin

chloroquine and derivatives 4

chloroquine 4

hydroxychloroquine 37

danoprevir / ritonavir

darunavir cobicistat

darunavir/cobicistat plus chloroquine

doxycycline 2

favipiravir 1

fluvoxamine

hydroxychloroquine plus macrolides 8

ivermectin 6

leronlimab

lopinavir / ritonavir plus ribavirin

lopinavir/ritonavir 5

lopinavir/ritonavir plus interferon ß-1a

lopinavir/ritonavir, ribavirin and interferon beta-1b 1

meplazumab

nitazoxanide

oseltamivir 1

oseltamivir plus chloroquin

remdesivir 6

Renin-angiotensin-system-acting agents 7

angiotensin converting enzyme inhibitors (ACEIs)

angiotensin receptor blockers (ARBs)

angiotensin-(1-7)

discontinuation of ACEI/ARB 1

RAS blocker withdrawal

rhACE2

ritonavir

tranexamic acid

triazavirin

umifenovir (arbidol) 3

control

prone positioning

miscellaneous

acetylcysteine

alpha lipoic acid 1

aviptadil

bevacizumab

bismuth

BLD-2660 (calpain inhibitor)

calcium channel blocker

camostat mesilate

continuous positive airway pressure (CPAP)

cytokine adsorption

diammonium glycyrrhizinate

dipyridamol

DPP-4 inhibitor

enoxaparin

famotidine 1

kinin-kallikrein inhibitors

levamisole

metformin

natural killer (NK) cells

nicotin

nitric oxide (gas Inhalation or releasing solution)

ozonated autohemotherapy

pamrevlumab

proton pump inhibitors (PPI) 6

PUL-042 inhalation solution

selinexor

statins

stem cells

tradipitant

tranilast

vaccines

bacTRL-Spike

BCG vaccination

Follow-us

This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N) and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.

   

- About - Our approach - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons